Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety study of linerixibat in primary biliary cholangitis-associated pruritus
2023-503465-33-00Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, open-label trial of linerixibat in primary biliary cholangitis (PBC) (2 arms), sponsored by GSK. Primary endpoint: Frequency and severity of adverse events. Started Jul 2020; status: completed.
02
Drugs
linerixibat
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2023-503465-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503465-33-00.